In Italy, TEPOV is being developed, a precision therapy against glioblastoma, a highly aggressive brain tumor, which aims to target the EV-3 anomaly and improve treatment prospects thanks to the drug AND-C4 from the biotech company Andremacon S.r.l. (translated)













